CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 706 enrolled
Drug / intervention
semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02461589
NCT02461589Phase 2Completed
CompareCT.gov

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Jun 3, 2015·Updated Jul 31, 2019

In Brief

A Phase 2 clinical trial evaluating semaglutide, liraglutide, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 706 participants across 150 sites in 10 countries.

Detailed Summary

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAustria, Canada, Czechia, Germany, Malaysia, Russia, Serbia, South Africa, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 3, 2015
Enrollment StartSep 21, 2015
Primary CompletionOct 13, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.1 years ago

Interventions

semaglutidedrug

Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.

liraglutidedrug

Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.

placebodrug

Administered subcutaneously ( s.c., under the skin) once daily.